400. Deputy Colm Burke asked the Minister for Health to confirm whether nirsevimab, the RSV vaccine, will be made available by the HSE for newborn babies from September 2026; and if she will make a statement on the matter. [53924/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Colm Burke under the heading Medicinal Products.
42 questions match, newest first.
750. Deputy Colm Burke asked the Minister for Health her views on extending publicly funded access to continuous glucose monitoring to all women with type 2 diabetes during pregnancy; and if she will make a statement on the matter. [52893/26]
751. Deputy Colm Burke asked the Minister for Health the number of people with a clinical diagnosis of type 1 diabetes who are currently ineligible for publicly funded continuous glucose monitoring access; and if she will make a statement on the matter. [52894/26]
752. Deputy Colm Burke asked the Minister for Health if she will consider widening access to continuous glucose monitoring (CGM) for women with type 2 diabetes during pregnancy (details supplied); and if she will make a statement on the matter. [52895/26]
753. Deputy Colm Burke asked the Minister for Health if the ongoing review of the preferred continuous glucose monitoring (CGM) sensors evaluation will encompass a consideration of ensuring that all patients with type one diabetes have access to CGM; and if she will make a statement on the matter. [52898/26]
754. Deputy Colm Burke asked the Minister for Health whether the ongoing review of the preferred continuous glucose monitoring (CGM) sensors evaluation will lead to a HTA of CGM sensors for patients with type 2 diabetes; and if she will make a statement on the matter. [52899/26]
898. Deputy Colm Burke asked the Minister for Health the steps being taken to ensure that a life-changing prostate cancer medication, RLT, known as Pluvicto, will be made available to medically suitable patients; and if she will make a statement on the matter. [47846/26]
356. Deputy Colm Burke asked the Minister for Health when the HSE will make a decision on reimbursement for the drug givinostat for patients with Duchenne muscular dystrophy; and if she will make a statement on the matter. [44850/26]
357. Deputy Colm Burke asked the Minister for Health to provide an update on the availability of the drug givinostat for patients with Duchenne muscular dystrophy; and if she will make a statement on the matter. [44851/26]
301. Deputy Colm Burke asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy; and if she will make a statement on the matter. [38284/26]
1240. Deputy Colm Burke asked the Minister for Health whether she is concerned about the promotion and sale of obesity medicines to under-18s for cosmetic weight-loss purposes by black-market actors; and if she will make a statement on the matter. [35309/26]
826. Deputy Colm Burke asked the Minister for Children, Disability and Equality whether she is concerned about the promotion and sale of obesity medicines to under-18s for cosmetic weight-loss purposes by black-market actors. [33442/26]
828. Deputy Colm Burke asked the Minister for Health the plans to tackle the promotion and sale of counterfeit obesity medicines online and offline which are in breach of the law, endanger public health and can contribute to organised crime. [32947/26]
895. Deputy Colm Burke asked the Minister for Health to clarify the 5 January 2026 memo from the HSE Codeine Working Group instructing that low dose codeine-containing products should not be stocked routinely in clinical areas in any HSE or HSE-funded service, and that they be removed from clinical stock by 5 June 2026; if she will confirm whether this reflects official Department of Health or HSE policy; and if she …
896. Deputy Colm Burke asked the Minister for Health to clarify claims in the 5 January 2026 HSE memo that low-dose codeine combination products are no more effective than paracetamol or ibuprofen alone; to identify the evidence base for this; to confirm current policy on managing chronic pain; and if she will make a statement on the matter. [32234/26]
897. Deputy Colm Burke asked the Minister for Health if she will provide details of the HPRA’s engagement with patient groups and stakeholders during its ongoing review of over-the-counter codeine medicines which commenced in November 2022, including which organisations were consulted and the nature of that engagement; and if she will make a statement on the matter. [32235/26]
898. Deputy Colm Burke asked the Minister for Health if she is satisfied that the HPRA review process on over-the-counter codeine medicines meets the required standards of transparency, proportionality and scientific rigour; and if she will make a statement on the matter. [32236/26]
899. Deputy Colm Burke asked the Minister for Health to clarify the basis for the 5 January 2026 memo of the HSE codeine working group on low-dose codeine stating that low dose paracetamol ibuprofen are no more effective than paracetamol or ibuprofen alone for the management of pain; to instruct that low-dose codeine products should not be stocked routinely in clinical areas in any HSE or HSE-funded service, to remov…
1173. Deputy Colm Burke asked the Minister for Health the steps planned to protect patients' safety in light of recent figures from the HPRA that show a major spike in the volume of illegally sourced obesity medicines detained last year. [32944/26]
1174. Deputy Colm Burke asked the Minister for Health the action she intends to take to protect patients from the health risks of the rapidly increasing availability of counterfeit obesity medicines which are untested, unregulated and unlicensed. [32945/26]
938. Deputy Colm Burke asked the Minister for Health the approach adopted when processing medicine reimbursement applications for combination therapies for cancer patients in the public system; and if she will make a statement on the matter. [17031/26]
1002. Deputy Colm Burke asked the Minister for Health to provide an update on the ongoing independent review by the Health Products Regulatory Authority on the method of sale and supply of codeine containing medicinal products that are currently available without prescription; and if she will make a statement on the matter. [69678/25]
1004. Deputy Colm Burke asked the Minister for Health in the event of the Health Products Regulatory Authority makes recommendations which provide that codeine containing medicinal products can only be made available through prescription, the mechanisms that will be put in place to assist those who are reliant on these products and who have been able to purchase them without prescription; and if she will make a state…
1005. Deputy Colm Burke asked the Minister for Health if the review being carried out by the Health Products Regulatory Authority on the method of sale and supply of codeine containing medicinal products are prepared to consider putting in place additional safeguards through pharmacies without the requirement for prescription; and if she will make a statement on the matter. [69681/25]
503. Deputy Colm Burke asked the Minister for Health the actions that have been taken to date to meet the Programme for Government commitment to investigate early access schemes for certain types of medicines; whether there are plans to consult with patient organisations as part of this process; and if she will make a statement on the matter. [66868/25]